. 2017 Nov 27;2(4):393–402. doi: 10.1007/s41669-017-0063-y

Table 2.

Healthcare costs for a glucose-lowering drug-treated type 2 diabetes population in Sweden between year 2006 and 2014 (million €)

	2006	2007	2008	2009	2010	2011	2012	2013	2014	Change from 2006 to 2014
Number of patients (n)	206,183	226,382	247,672	268,145	290,514	310,736	331,092	348,625	366,492	+160,309 (+77.8%)
Inpatient care	355	417	463	500	565	634	726	756	783	+428 (+120%)
Outpatient care	112	127	150	161	180	218	240	276	303	+191 (+170%)
Primary care (estimated)^a	228	250	274	296	321	343	366	385	405	+177 (+78%)
Medications	140	157	173	181	178	181	180	183	192	52 (+37%)
Glucose-lowering drugs	39	44	52	57	63	67	74	78	84	45 (+115%)
Other medications	101	113	121	124	115	114	106	106	109	8 (+8%)
Total healthcare costs^b	835	951	1060	1138	1244	1375	1511	1600	1684	+849 (+102%)

^aEstimated for the study population based on primary care resource use reported in an observational study by Sabale et al. [19]

^bBased on observational data collected from National Swedish Registries and an observational study by Sabale et al. [19]